Expression of Concern
This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.
This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.
Research Paper Volume 11, Issue 15 pp 5848—5863
Sodium cantharidate targets STAT3 and abrogates EGFR inhibitor resistance in osteosarcoma
Figure 5. Combined treatment with sodium cantharidate and erlotinib enhances osteosarcoma growth suppression in nude mice. Nude mice were subcutaneously implanted with MG63 cells, randomly divided into four groups, and treated with saline (control), SC, erlotinib, or SC plus erlotinib for 4 weeks. (A) Mean tumor volumes in each experimental group. (B) Tumor wet weights at sacrifice (day 28 post-inoculation). (C) Body weight measurements. (D) Western blot analysis of phospho-EGFR, phospho-STAT3, Bcl-2, and MMP2 in excised tumor tissues. (E) Phospho-EGFR and (F) phosphor-STAT3 detection thorough immunohistochemistry in excised xenografts. Magnification, 100x. Sc, sodium cantharidate; Er, erlotinib.